Skip to main content

Table 3 Pathway enrichment analysis of statin-dysregulated genes

From: Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients

Pathway (1) or Disease (2) or Regulator (3) P value Prediction Activation Z-score # Genes
1. Superpathway of cholesterol biosynthesis 1.2 × 10−40 increased 4.36 19
1. Fatty acid metabolism 2.5 × 10−09 increased 1.82 18
1. LXR/RXR signaling 2.3 × 10−08 increased 1.43 8
1. AMPK signaling 9.9 × 10−03 decreased −1.26 4
2. Metabolic disease 9.6 × 10− 08   n.a. 31
2. Insulin resistance 6.9 × 10−06   n.a. 10
2. Type II diabetes mellitus 1.3 × 10−03   n.a. 15
3. SREBF1 1.5 × 10−34 activated 4.64 29
3. SREBF2 1.3 × 10−56 activated 4.74 31
3. SCAP 3.4 × 10−52 activated 4.84 27
3. INSIG1 1.3 × 10−40 inhibited −3.77 26
  1. Main enriched metabolic and signaling pathways (1), disease processes (2) and regulators (3) modulated by statin treatment in the propensity score-matched patient cohort (n = 314) are shown. The analysis was performed using the Ingenuity Pathway Analysis (IPA) using a list of 98 statin-regulated genes (see Additional file 1: Table S2). The total number of statin-regulated genes assigned to each pathway or disease process is given under the “# genes” column. For regulators (3), the number of downstream target genes is given (all corresponding gene symbols are listed in Additional file 1: Table S4). The Z-score indicates the match between observed and predicted up- or downregulation patterns. Abbreviations: LXR/RXR liver X receptor/retinoid X receptor, AMPK AMP-activated protein kinase, SREBF sterol regulatory element-binding factor, SCAP SREBP-cleavage activating protein, INSIG1 insulin induced gene-1, n.a. no molecular activity prediction available